Ownership and insider activity for Monopar Therapeutics Inc. (MNPR): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase...
Price
| Price | $101.45 |
| Market Cap | $680M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-26 | Tsuchimoto Kim R | M-Exempt | 2,035 | $28K |
| 2026-08-26 | Tsuchimoto Kim R | M-Exempt | 2,055 | $62K |
| 2026-08-26 | Tsuchimoto Kim R | M-Exempt | 2,035 | $28K |
| 2026-08-26 | Tsuchimoto Kim R | S-Sale | 485 | $53K |
| 2026-08-26 | Tsuchimoto Kim R | S-Sale | 615 | $67K |
| 2026-08-26 | Tsuchimoto Kim R | S-Sale | 700 | $77K |
| 2026-08-26 | Tsuchimoto Kim R | M-Exempt | 2,055 | $62K |
| 2026-08-26 | Tsuchimoto Kim R | S-Sale | 1,098 | $123K |
| 2026-08-26 | Tsuchimoto Kim R | S-Sale | 602 | $68K |
| 2026-08-26 | Tsuchimoto Kim R | S-Sale | 590 | $67K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.1M | $9.0M | $6.9M | $13.2M | $16.7M | $20.3M | $8.2M | $7.3M | $45.8M | $61.8M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | $4.9M | 0 | $14.4M | $78.6M |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $2.1M | $9.1M | $7.3M | $13.2M | $16.8M | $20.5M | $13.2M | $7.3M | $60.3M | $140.5M |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 | $61228 | $12646 | 0 | $254921 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | $730.6M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $2.9M | $9.9M | $7.3M | $13.4M | $16.9M | $20.5M | $13.2M | $7.3M | $60.3M | $140.7M |
| Accounts Payable | $64510 | $311867 | $399551 | $724165 | $1.2M | $1.6M | $3.1M | $1.8M | $2.3M | $2.7M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $64510 | $311867 | $399551 | $724165 | $1.2M | $1.6M | $3.1M | $1.8M | $5.3M | $2.7M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $64510 | $311867 | $399551 | $724165 | $1.2M | $1.6M | $3.1M | $1.8M | $5.3M | $2.9M |
| Retained Earnings | -$1.9M | -$18.4M | -$21.7M | -$25.9M | -$32.2M | -$41.3M | -$51.8M | -$60.2M | -$75.8M | -$89.5M |
| Total Equity | $2.8M | $9.6M | $6.9M | $12.6M | $15.7M | $18.9M | $10.1M | $5.6M | $55.0M | $137.8M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 | $8408 | 0 | 0 | $154920 |
| Net Debt | -$2.1M | -$9.0M | -$6.9M | -$13.2M | -$16.7M | -$20.3M | -$13.1M | -$7.3M | -$60.2M | -$140.2M |
| Working Capital | $2.0M | $8.8M | $6.9M | $12.5M | $15.6M | $18.9M | $10.0M | $5.6M | $55.0M | $137.7M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 33.56 |
Profitability
| Return on Equity | -13.08% |
| Return on Invested Capital | -16.89% |
| Return on Assets | -13.22% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: AKBA · BCYC · CMPX · FDMT · FULC · GOSS · KALV
Explore sector: Healthcare · Biotechnology
More sections of MNPR: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks